MAPT and tauopathy: Thus, integrating cAMP/PKA/Tau and GSKIP and Aβ42 and Aβ40 biomarkers for the detection of different types of AD and tauopathies and for the prediction of treatment outcomes could improve the clinical practice of precision medicine.